





CANCER RESEARCH NETWORK

2025 Impact Report

“ 2025 has been memorable in so many ways, and this report highlights some key SWOG milestones and accomplishments from the year.

Coming to the close of our current grant cycles gives us a chance to take stock of SWOG’s longer-term accomplishments as well. That accounting is impressive – check out “The Long View” below.

It has been an honor to lead SWOG over these years. I’m extraordinarily proud of what we have accomplished and the lives we’ve saved and improved. 2026 and beyond will see even more extraordinary SWOG achievements and impact. ”

— Charles D. Blanke, MD
Chair, SWOG Cancer Research Network





National Clinical Trials Network



Community Oncology Research Program

Our Data

8 SWOG trials activated

6 SWOG trials closed

32 clinical and translational concepts reviewed by leadership

24 requests for trial data granted


3,686 patients enrolled on all SWOG-run trials, not counting screening registrations

81 journal articles published

42% published in high impact factor journals

73 oral or poster presentations made

23% of presentations were oral



Our Highlights

Based on the results of S1826, the FDA granted priority review of an application for using the trial’s nivolumab + AVD combination in untreated adult and pediatric classic Hodgkin lymphoma. An approval decision is expected by spring. Also in 2025: three-year follow-up data from S1826 confirmed the durability of the combination’s benefit.



25 Years of Impact

SWOG Early Stage Investigators Training Course workshop in March 2000 ...

Since the first Young Investigators Training Course workshop in March 2000 ...

... we completed the course, comprising 27 cohorts of ESIIC graduates, which have generated more than 300,000 studies, and more than 100% have presented at an ASCO Annual Meeting. When graduates talk about the program, they highlight networking • mentoring • hands-on experience as among the most valuable aspects of the course. To learn more, visit thehopefoundation.org.

We celebrated the 25th anniversary of SWOG’s flagship mentoring and training program for investigators – now known as the Leadership and Project Development (LEAP) course (formerly our Young/Early-Stage Investigator Training Course).

More than 130 researchers have completed the course, which has directly led to more than 50 SWOG clinical trials and has nurtured numerous SWOG leaders. Over the years, program graduates have been authors on more than 20,000 publications, which in turn have been cited more than half a million times.

Early in 2025, one recent program graduate, **Dr. Jonathan Sham**, activated the first clinical trial born and bred in SWOG’s palliative care committee. S2408 asks whether the drug lanreotide can reduce the risk of pancreatic fistula following surgery for pancreatic cancer.



SWOG submitted applications for the next cycle of NCI grants to support our NCTN Network Operations Center (NOC) and Statistics & Data Management Center (SDMC). Our NOC grant earned an “outstanding” score, our SDMC grant an “exceptional.”

We are now crafting our application for the next round of NCORP Research Base awards.

The Long View: Quantifying SWOG’s grant cycles just ending (2018 – 2025)


>80 clinical trials launched

>30,000 volunteers enrolled to our clinical trials

>600 research abstracts presented


>700 peer-reviewed manuscripts published

>600 new member sites welcomed




We appointed Dr. Raymond Osarogiabon as our first executive officer for community site engagement. He will work to boost the involvement of our community-based members in all stages of the development and conduct of SWOG trials.

We welcomed Dr. Amrita Krishnan as the new chair of our Barlogie-Salmon Myeloma Committee.




The myeloMATCH umbrella trial in myeloid malignancies, in its first full calendar year, exceeded its screening protocol enrollment targets. SWOG leads the screening protocol and is proud to play a key role in what may be the most broadly collaborative trial ever undertaken across the NCTN and NCORP.

We published the primary results of our S1702 trial, led by **Dr. Terri Parker**, which found that the drug isatuximab generated a high hematologic response rate and organ response rate in patients with relapsed or refractory AL amyloidosis.



Dr. Anne Chiang launched the S2409 PRISM trial, the first study in small cell lung cancer to use molecular subtyping to assign patients to specific cohorts testing new targeted treatments. For more than a decade now, our Lung-MAP trial has successfully applied a similar model in testing treatments for non-small cell lung cancer.

SWOG Clinical Trials Partnerships advanced from startup mode into full-scale production with the activation of its first two clinical trials – 21CTP.Leuk01 and 21CTP.HN01 MONITOR. Expect more activations in 2026.



Pragmatica-Lung

A real-world clinical trial for patients whose non-small cell lung cancer has returned after chemo- and immuno-therapy

We reported initial results from our landmark S2302 Pragmatica-Lung trial. Although the study did not meet its primary endpoint, it was a resounding success as a model for leaner, faster clinical trials that are easier for our sites to open and conduct, and that rapidly enroll a broadly representative group of patients.


THE HOPE FOUNDATION FOR CANCER RESEARCH

Resilient Partnership:


Navigating the Inconstant Funding Landscape

Research doesn’t happen in a vacuum, and it certainly doesn’t follow a straight line. Increasingly, as federal funding priorities have fluctuated, The Hope Foundation for Cancer Research has stepped up as a dedicated partner to help SWOG navigate the highs and lows. By bridging financial gaps and providing flexible resource management, we’ve helped to ensure that our most important projects stay on track, no matter which way the winds blow in Washington.


We have achieved this stability by diversifying our support beyond traditional nonfederal grants. Our strategy today rests on three key pillars:




Philanthropic Growth: With the help of SWOG members, we have cultivated meaningful partnerships with grateful patient-donors. These individuals are personally invested in SWOG’s mission, providing new philanthropic support to fuel critical SWOG research that federal budgets might overlook.



Industry Collaboration: The nature of industry support has evolved; it is no longer about simple unrestricted grantmaking, but about a shared vision. By leveraging our unique infrastructure, we provide the expertise and connections required to advance world-class research. We foster a collaborative environment where industry investment and scientific breakthroughs happen in tandem.




Financial Stewardship: At our core, we uphold a rigorous commitment to financial responsibility. By managing a diverse investment portfolio and maintaining an agile operational structure, we can quickly meet emerging needs across SWOG’s network.



In an era of unpredictable federal shifts, these efforts allow The Hope Foundation to serve as a stabilizing force. While the landscape of public funding may fluctuate, our role remains constant: to buffer the impact of volatility and ensure that vital innovation continues uninterrupted.

As always, the insights of our community are invaluable to our growth. I welcome the opportunity to connect and discuss our shared commitment to advancing research in the year ahead.


Jo Horn
President & CEO



HOPE BY THE NUMBERS 2025


\$2.7 MILLION

Funding approved in support of SWOG research



182

Travelers funded to attend group meetings



9

New peer-reviewed research proposals awarded

